CSIMarket



Biogen Inc   (BIIB)
Other Ticker:  
 
 

BIIB's Net Income Growth by Quarter and Year

Biogen Inc 's Net Income results by quarter and year




BIIB Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -20.60 357.50 1,439.70
III Quarter September - 318.10 703.90 1,545.90
II Quarter June - 1,025.50 1,606.50 1,494.10
I Quarter March 218.50 404.60 1,392.60 1,408.80
FY   218.50 1,727.60 4,060.50 5,888.50



BIIB Net Income first quarter 2022 Y/Y Growth Comment
Biogen Inc reported drop in Net Income in the first quarter 2022 by -46% to $ 218.50 millions, from the same quarter in 2021.
The fall in the first quarter 2022 Biogen Inc 's Net Income compares unfavorably to the Company's average Net Income increase of 10.23%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Net Income growth. While Biogen Inc ' s Net Income meltdown of -46% ranks overall at the positon no. 759 in the first quarter 2022.




BIIB Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - -75.17 % 52.37 %
III Quarter September - -54.81 % -54.47 % 7.14 %
II Quarter June - -36.17 % 7.52 % 63.29 %
I Quarter March -46 % -70.95 % -1.15 % 20.29 %
FY   - -57.45 % -31.04 % 31.62 %

Financial Statements
Biogen Inc 's first quarter 2022 Net Income $ 218.50 millions BIIB's Income Statement
Biogen Inc 's first quarter 2021 Net Income $ 404.60 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Net Income Growth >>


BIIB Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - -49.21 % -6.87 %
III Quarter September - -68.98 % -56.18 % 3.47 %
II Quarter June - 153.46 % 15.36 % 6.05 %
I Quarter March - 13.17 % -3.27 % 49.1 %
FY (Year on Year)   - -57.45 % -31.04 % 31.62 %




Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #56
Overall #759

Net Income Y/Y Growth Statistics
High Average Low
368.67 % 10.23 % -85.39 %
(Sep. 30, 2006)   (June 30. 2006)
Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #56
Overall #759
Net Income Y/Y Growth Statistics
High Average Low
368.67 % 10.23 % -85.39 %
(Sep. 30, 2006)   (June 30. 2006)

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Biogen Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
4345.95 % 76.53 % -68.98 %
(Sep. 30, 2004)  


BIIB's I. Quarter Q/Q Net Income Comment
I. Quarter 2022Cyclical Biogen Inc in the circumstances net loss of $ 218.50 millionsCyclical circumstances appear to have added to Biogen Inc 's return to positive trends, as BIIB clinchesNet Income of $ 218.50 millions in the I. Quarter 2022 emanate net loss-20.60 millions in the forth quarter. Biogen Inc announced in the I. Quarter 2022 Net Income of $ 218.50 millions compare to net loss recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Biogen Inc achieved highest sequential Net Income growth. While Biogen Inc 's Net Income growth quarter on quarter, overall rank is 0.


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Net Income Q/Q Growth Statistics
High Average Low
4345.95 % 76.53 % -68.98 %
(Sep. 30, 2004)  


BIIB's I. Quarter Q/Q Net Income Comment
I. Quarter 2022Cyclical Biogen Inc in the factors net loss of $ 218.50 millionsCyclical factors have led to Biogen Inc 's restoration of recovery, as BIIB clinchesNet Income of $ 218.50 millions in the I. Quarter 2022 emerging from net loss-20.60 millions in the forth quarter. Biogen Inc announced in the I. Quarter 2022 Net Income of $ 218.50 millions compare to net loss recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Biogen Inc achieved highest sequential Net Income growth. While Biogen Inc 's Net Income growth quarter on quarter, overall rank is 0.


Biogen Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Net Income 12 Months Ending $ 1,541.50 $ 1,727.60 $ 2,105.70 $ 2,491.50 $ 3,072.50
Y / Y Net Income Growth (TTM) -49.83 % -57.45 % -59.05 % -58.37 % -47.68 %
Year on Year Net Income Growth Overall Ranking # 735 # 223 # 98 # 812 # 353
Seqeuential Net Income Change (TTM) -10.77 % -17.96 % -15.48 % -18.91 % -24.33 %
Seq. Net Income Growth (TTM) Overall Ranking # 759 # 248 # 110 # 896 # 381




Cumulative Net Income growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Net Income decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Net Income fall would be -49.83% year on year to $1,542 millions.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 223 to 735.

Net Income TTM Q/Q Growth Statistics
High Average Low
368.67 %
10.23 %
-85.39 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 51
Overall # 735

Net Income TTM Y/Y Growth Statistics
High Average Low
1560.25 %
54.67 %
-75.52 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 56
S&P 500 # 759
Cumulative Net Income growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Net Income decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Net Income drop would be -49.83% year on year to $1,542 millions.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 223 to 735.

Net Income TTM Q/Q Growth Statistics
High Average Low
368.67 %
10.23 %
-85.39 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 51
Overall # 735

Net Income TTM Y/Y Growth Statistics
High Average Low
1560.25 %
54.67 %
-75.52 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 56
S&P 500 # 759




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
BIIB's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for BIIB's Competitors
Net Income Growth for Biogen Inc 's Suppliers
Net Income Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Net Income drop for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2022
Chemed Corporation-1.88%$ -1.882 millions
Biomx Inc -2.77%$ -2.773 millions
Ironwood Pharmaceuticals inc -2.82%$ -2.818 millions
Corcept Therapeutics Inc-2.85%$ -2.847 millions
Msa Safety Inc-2.89%$ -2.891 millions
Merit Medical Systems Inc-3.77%$ -3.769 millions
Addus Homecare Corporation-4.77%$ -4.767 millions
Idexx Laboratories Inc-5.05%$ -5.054 millions
Hca Healthcare Inc -7.28%$ -7.278 millions
National Research Corporation-7.51%$ -7.506 millions
Amgen Inc -10.33%$ -10.328 millions
Regeneron Pharmaceuticals Inc -12.71%$ -12.706 millions
Organon and Co -12.78%$ -12.782 millions
Intuitive Surgical Inc -15.12%$ -15.119 millions
Apollo Medical Holdings Inc -16.50%$ -16.496 millions
Encompass Health Corporation-17.09%$ -17.093 millions
Molecular Templates Inc -19.30%$ -19.296 millions
Royalty Pharma Plc-19.43%$ -19.434 millions
Natus Medical Inc-20.58%$ -20.576 millions
Fulgent Genetics Inc -23.49%$ -23.486 millions
Quest Diagnostics Inc-23.88%$ -23.878 millions
Fonar Corporation-24.12%$ -24.122 millions
Hologic Inc-26.49%$ -26.488 millions
Integra Lifesciences Holdings Corp-27.52%$ -27.521 millions
Universal Health Services Inc -27.77%$ -27.765 millions
National Healthcare Corp-27.97%$ -27.966 millions
Incyte Corp-29.03%$ -29.033 millions
Davita Inc -29.44%$ -29.439 millions
Reynolds Consumer Products Inc -29.73%$ -29.730 millions
Semler Scientific inc -31.11%$ -31.105 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

EJH's Profile

Stock Price

EJH's Financials

Business Description

Fundamentals

Charts & Quotes

EJH's News

Suppliers

EJH's Competitors

Customers & Markets

Economic Indicators

EJH's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071